Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

× No keyword cloud information.

16 in total

1. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors: H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal: J Neurol Neurosurg Psychiatry Date: 1997-10 Impact factor: 10.154

2. Effects of long-term administration of the antiepileptic drug--sodium valproate upon the ultrastructure of hepatocytes in rats.

Authors: M E Sobaniec-Lotowska
Journal: Exp Toxicol Pathol Date: 1997-08

3. Origin and functional consequences of the complex I defect in Parkinson's disease.

Authors: R H Swerdlow; J K Parks; S W Miller; J B Tuttle; P A Trimmer; J P Sheehan; J P Bennett; R E Davis; W D Parker
Journal: Ann Neurol Date: 1996-10 Impact factor: 10.422

4. Fulminant hepatitis. An ultrastructural study.

Authors: T F McCaul; E A Fagan; G Tovey; B Portmann; R Williams; A J Zuckerman
Journal: J Hepatol Date: 1986 Impact factor: 25.083

Review 5. Fulminant and subfulminant liver failure: definitions and causes.

Authors: J Bernuau; B Rueff; J P Benhamou
Journal: Semin Liver Dis Date: 1986-05 Impact factor: 6.115

Review 6. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.

Authors: B Fromenty; D Pessayre
Journal: Pharmacol Ther Date: 1995 Impact factor: 12.310

7. Portal hypertension in fulminant viral hepatitis.

Authors: D Lebrec; O Nouel; J Bernuau; B Rueff; J P Benhamou
Journal: Gut Date: 1980-11 Impact factor: 23.059

8. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production.

Authors: E Nissinen; P Kaheinen; K E Penttilä; J Kaivola; I B Lindén
Journal: Eur J Pharmacol Date: 1997-12-11 Impact factor: 4.432

9. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.

Authors: A H Rajput; W Martin; M H Saint-Hilaire; E Dorflinger; S Pedder
Journal: Neurology Date: 1997-10 Impact factor: 9.910

10. Platelet morphology in Parkinson's disease: an electron microscopic study.

Authors: S A Factor; E Ortof; M P Dentinger; R Mankes; K D Barron
Journal: J Neurol Sci Date: 1994-03 Impact factor: 3.181

1 in total

Review 1. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.

Authors: Nuno Borges
Journal: Drug Saf Date: 2003 Impact factor: 5.606

1 in total